MA45803A1 - Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage - Google Patents
Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilageInfo
- Publication number
- MA45803A1 MA45803A1 MA45803A MA45803A MA45803A1 MA 45803 A1 MA45803 A1 MA 45803A1 MA 45803 A MA45803 A MA 45803A MA 45803 A MA45803 A MA 45803A MA 45803 A1 MA45803 A1 MA 45803A1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrido
- treatment
- cartilage
- substituted indoles
- cartilage disorders
- Prior art date
Links
- 208000015100 cartilage disease Diseases 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 102000055008 Matrilin Proteins Human genes 0.000 abstract 1
- 108010072582 Matrilin Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des 9h-pyrido [3,4-b] indoles à substitution 8-aryle et 8-hétéroaryle de formule (i), dans laquelle a, e, g, r1 à r6 et r10 sont tels que définis dans les revendications, qui stimulent la synthèse de la chondrogenèse et de la matrice cartilagineuse et peuvent être utilisés dans le traitement de troubles et d'affections du cartilage dans lesquels une régénération du cartilage endommagé est souhaitée, par exemple des maladies articulaires telles que l'arthrose. L'invention concerne en outre des procédés de synthèse des composés de formule (i), leur utilisation comme composés pharmaceutiques et des compositions pharmaceutiques les comprenant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (fr) | 2016-11-07 | 2016-11-07 | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
| PCT/EP2017/078026 WO2018083157A1 (fr) | 2016-11-07 | 2017-11-02 | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45803A1 true MA45803A1 (fr) | 2020-05-29 |
| MA45803B1 MA45803B1 (fr) | 2020-10-28 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45803A MA45803B1 (fr) | 2016-11-07 | 2017-11-02 | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11130755B2 (fr) |
| EP (3) | EP3318563A1 (fr) |
| JP (1) | JP7046063B2 (fr) |
| KR (1) | KR102490199B1 (fr) |
| CN (1) | CN110382496B (fr) |
| AR (1) | AR110136A1 (fr) |
| AU (2) | AU2017353381B2 (fr) |
| CA (1) | CA3042332A1 (fr) |
| CL (1) | CL2019001251A1 (fr) |
| CO (1) | CO2019005090A2 (fr) |
| CR (1) | CR20190217A (fr) |
| DK (1) | DK3535263T3 (fr) |
| DO (1) | DOP2019000112A (fr) |
| EA (1) | EA038365B1 (fr) |
| EC (1) | ECSP19031458A (fr) |
| ES (1) | ES2837765T3 (fr) |
| HR (1) | HRP20201754T1 (fr) |
| HU (1) | HUE052187T2 (fr) |
| IL (1) | IL265982B (fr) |
| LT (1) | LT3535263T (fr) |
| MA (1) | MA45803B1 (fr) |
| MX (1) | MX383580B (fr) |
| MY (1) | MY189589A (fr) |
| PE (1) | PE20191032A1 (fr) |
| PH (1) | PH12019500997B1 (fr) |
| PT (1) | PT3535263T (fr) |
| RS (1) | RS61172B1 (fr) |
| SG (1) | SG11201903195YA (fr) |
| SI (1) | SI3535263T1 (fr) |
| TN (1) | TN2019000143A1 (fr) |
| TW (1) | TWI753966B (fr) |
| UY (1) | UY37473A (fr) |
| WO (1) | WO2018083157A1 (fr) |
| ZA (1) | ZA201902111B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (fr) | 2016-11-07 | 2018-05-09 | Sanofi | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
| CN111936490A (zh) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| EP3768267B1 (fr) * | 2018-03-20 | 2025-05-14 | Icahn School of Medicine at Mount Sinai | Dérivés de beta-carboline en tant qu'inhibiteurs de dyrk1a pour le traitement de par ex. diabetes |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| KR20220044721A (ko) * | 2019-08-06 | 2022-04-11 | 도메인 테라퓨틱스 | 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물 |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) * | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (fr) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline-thromboxane-synthetase |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1134221A1 (fr) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Bêta-carbolines substituées comme inhibiteurs de lkB kinase |
| EP1268477B1 (fr) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Beta-carbolines substituees ayant une activite inhibitrice de l'ikb-kinase |
| JP4599501B2 (ja) | 2001-11-07 | 2010-12-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体 |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| WO2006013739A1 (fr) | 2004-08-04 | 2006-02-09 | Konica Minolta Holdings, Inc. | Dispositif électroluminescent organique, dispositif d’éclairage et affichage |
| CA2658511C (fr) | 2006-08-25 | 2019-02-19 | Ares Trading S.A. | Utilisation de compose fgf-18 dans le traitement de troubles du cartilage |
| WO2008132454A1 (fr) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines et leur utilisation comme agents d'imagerie |
| FR2916380B1 (fr) * | 2007-05-21 | 2009-07-31 | Saint Gobain | Procede et dispositif de surmoulage d'un element vitre par une portion de joint comportant un insert, vitrage et insert notamment pour ce procede. |
| WO2010038153A1 (fr) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Utilisation d'activateurs des facteurs de transcription sox pour stimuler la chondrogenèse |
| US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2455378A1 (fr) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (fr) | 2016-11-07 | 2018-05-09 | Sanofi | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/fr not_active Withdrawn
-
2017
- 2017-11-02 HR HRP20201754TT patent/HRP20201754T1/hr unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/fr not_active Ceased
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 CA CA3042332A patent/CA3042332A1/fr active Pending
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/fr active Pending
- 2017-11-02 PH PH1/2019/500997A patent/PH12019500997B1/en unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active Active
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/fr active Active
- 2017-11-02 MX MX2019005308A patent/MX383580B/es unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es active IP Right Grant
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US12275733B2/en active Active
-
2025
- 2025-03-03 US US19/068,406 patent/US20250333412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45803B1 (fr) | Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA31447B1 (fr) | Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1 | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA41625A (fr) | Composés de benzazépine dicarboxamide | |
| TN2009000551A1 (fr) | Nouveaux composes chimiques | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA33768B1 (fr) | Triazolopyridines | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA35271B1 (fr) | Antagonistes de trpm8 et leur utilisation dans des traitements | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| MA38648B1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
| MA39582A1 (fr) | Composés de 6,7-dihydropyrazolo [1,5-?]pyrazin -4 (5h)-one et leur utilisation en tant que modulateurs négatifs allostériques des récepteurs métabotropiques du glutamate |